BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34135752)

  • 1. Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil.
    Fulone I; Silva MT; Lopes LC
    Front Pharmacol; 2021; 12():638001. PubMed ID: 34135752
    [No Abstract]   [Full Text] [Related]  

  • 2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.
    Bernardo M; Rico-Villademoros F; García-Rizo C; Rojo R; Gómez-Huelgas R
    Adv Ther; 2021 May; 38(5):2491-2512. PubMed ID: 33826090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
    Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
    J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.
    Kishimoto T; Hagi K; Nitta M; Kane JM; Correll CU
    World Psychiatry; 2019 Jun; 18(2):208-224. PubMed ID: 31059621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
    Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
    Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with laxative use in schizophrenia patients treated with second-generation antipsychotics.
    Lin CH; Chan HY; Hsu CC; Chen FC
    Eur Neuropsychopharmacol; 2021 Feb; 43():139-146. PubMed ID: 33419642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study.
    Chyou TY; Nishtala R; Nishtala PS
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):692-700. PubMed ID: 32301237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
    Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
    Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Clozapine vs Other Second-Generation Antipsychotics on Hospitalization and Seclusion: A Retrospective Mirror-Image Study in a Japanese Public Psychiatric Hospital.
    Misawa F; Suzuki T; Fujii Y
    J Clin Psychopharmacol; 2017 Dec; 37(6):664-668. PubMed ID: 29045304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study.
    Brodeur S; Vanasse A; Courteau J; Stip E; Lesage A; Fleury MJ; Courteau M; Roy MA
    Acta Psychiatr Scand; 2022 May; 145(5):456-468. PubMed ID: 35158404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.
    Cooper D; Moisan J; Gaudet M; Abdous B; Grégoire JP
    Can J Psychiatry; 2005 Dec; 50(14):901-8. PubMed ID: 16494259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of hospital contacts with acute kidney injury after initiation of second-generation antipsychotics in older adults: a Danish population-based cohort study.
    Sharon R; Lange T; Aakjær M; Brøgger Kristiansen S; Baltzer Houlind M; Andersen M
    Eur J Clin Pharmacol; 2022 Aug; 78(8):1341-1349. PubMed ID: 35639132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period.
    Barak Y; Mirecki I; Knobler HY; Natan Z; Aizenberg D
    Psychopharmacology (Berl); 2004 Sep; 175(2):215-9. PubMed ID: 14760515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.